Immunotherapy For Breast Cancer
Immunotherapy drugs for breast cancer have until recently been relatively ineffective when compared to the sometimes dramatic responses to these drugs in cancers such as melanoma and lung cancer. This changed in March 2019 with the accelerated approval of the drug Tecentriq (atezolizumab) for women and men with metastatic (stage 4) or locally advanced and unresectable triple negative breast cancer. The approval comes along with a companion test to help select which people who might benefit from the treatment....